|
Characteristics
|
Patients, n = 61
|
|---|
|
Median age (range)
|
65 (40–84)
|
|---|
|
Sex
| |
|
Male
|
29 (48%)
|
|
Female
|
32 (53%)
|
|
Race
| |
|
White
|
39 (64%)
|
|
Black
|
21 (34%)
|
|
Other
|
1 (2%)
|
|
Histology
| |
|
Adenocarcinoma
|
30 (49%)
|
|
Squamous
|
18 (30%)
|
|
NSCLC NOS*
|
13 (21%)
|
|
T Stage
| |
|
T1
|
9 (15%)
|
|
T2
|
20 (33%)
|
|
T3
|
11 (18%)
|
|
T4
|
19 (31%)
|
|
Tx
|
2 (3%)
|
|
N Stage
| |
|
N0
|
1 (2%)
|
|
N2
|
32 (52%)
|
|
N3
|
28 (46%)
|
|
AJCC Stage (V.7)
| |
|
IIIA
|
22 (36%)
|
|
IIIB
|
39 (64%)
|
|
Radiation Technique
| |
|
3-D Conformal
|
45 (74%)
|
|
IMRT
|
9 (15%)
|
|
3-D Conformal & IMRT
|
7 (11%)
|
|
Radiation Dose, median (range)
|
66 Gy (39.6-74 Gy)
|
|
Treatment Planning Margins, median (range)
| |
|
GTV to CTV expansion
|
0.5 cm (0–1 cm)
|
|
CTV to PTV expansion
|
1 cm (0.3-2.5 cm)
|
|
Use of daily On-board Imaging (OBI)
|
24 (39%)
|
|
Concurrent Chemotherapy
|
55 (90%)
|
- *NSCLC NOS- non-small cell carcinoma not otherwise specified.
